Takeda Pharmaceutical Co Ltd (TAK)
13.64
+0.06
(+0.48%)
USD |
NYSE |
Nov 15, 14:23
Takeda Pharmaceutical Gross Profit Margin (Quarterly): 66.47% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 66.47% |
| June 30, 2024 | 67.97% |
| March 31, 2024 | 63.60% |
| December 31, 2023 | 65.85% |
| September 30, 2023 | 67.06% |
| June 30, 2023 | 69.67% |
| March 31, 2023 | 67.60% |
| December 31, 2022 | 69.36% |
| September 30, 2022 | 69.53% |
| June 30, 2022 | 69.88% |
| March 31, 2022 | 64.69% |
| December 31, 2021 | 68.78% |
| September 30, 2021 | 67.35% |
| June 30, 2021 | 74.59% |
| March 31, 2021 | 67.10% |
| December 31, 2020 | 69.75% |
| September 30, 2020 | 68.36% |
| June 30, 2020 | 70.31% |
| March 31, 2020 | 67.84% |
| December 31, 2019 | 67.47% |
| September 30, 2019 | 66.68% |
| June 30, 2019 | 65.64% |
| March 31, 2019 | 60.70% |
| December 31, 2018 | 72.26% |
| September 30, 2018 | 74.29% |
| Date | Value |
|---|---|
| June 30, 2018 | 73.19% |
| March 31, 2018 | 72.34% |
| December 31, 2017 | 70.85% |
| September 30, 2017 | 71.87% |
| June 30, 2017 | 73.04% |
| March 31, 2017 | 67.71% |
| December 31, 2016 | 68.28% |
| September 30, 2016 | 66.06% |
| June 30, 2016 | 68.80% |
| March 31, 2016 | 67.94% |
| December 31, 2015 | 70.36% |
| September 30, 2015 | 70.23% |
| June 30, 2015 | 72.86% |
| March 31, 2015 | 69.26% |
| December 31, 2014 | 71.47% |
| September 30, 2014 | 70.71% |
| June 30, 2014 | 71.29% |
| March 31, 2014 | 70.19% |
| December 31, 2013 | 71.33% |
| September 30, 2013 | 71.24% |
| June 30, 2013 | 71.26% |
| March 31, 2013 | 65.40% |
| December 31, 2012 | 70.04% |
| September 30, 2012 | 70.99% |
| June 30, 2012 | 74.06% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
63.60%
Minimum
Mar 2024
74.59%
Maximum
Jun 2021
68.16%
Average
67.90%
Median
Gross Profit Margin (Quarterly) Benchmarks
| HUTCHMED (China) Ltd | -- |
| Astellas Pharma Inc | 80.74% |
| Nxera Pharma Co Ltd | 78.44% |
| PeptiDream Inc | 89.26% |
| Healios KK | 86.35% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 4.01% |
| Return on Assets | 1.91% |
| Return on Invested Capital | 2.37% |
| Profit Margin (Quarterly) | 7.83% |
| Operating Margin (Quarterly) | 23.27% |
| Return on Net Operating Assets | 2.13% |